Back to top
more

Envista (NVST)

(Real Time Quote from BATS)

$16.58 USD

16.58
8,484,226

+0.08 (0.49%)

Updated Aug 9, 2024 09:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

NVST or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVST vs. BSX: Which Stock Is the Better Value Option?

IDEXX (IDXX) CAG Placement Grows Globally Amid Cost Woes

by Zacks Equity Research

IDEXX's (IDXX) global reference lab revenues are growing organically, reflecting growth in the United States and the international markets.

Here's Why You Should Add Alcon Stock (ALC) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Alcon (ALC) backed by robust second-quarter performance and raised 2021 outlook.

NuVasive (NUVA) Expands Training Opportunities With New Center

by Zacks Equity Research

NuVasive's (NUVA) East Coast Experience Center reflects the company's commitment to provide best quality surgeon education and training to enhance the standard of patient care in spine surgery.

Here's Why You Should Add Omnicell (OMCL) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Omnicell (OMCL) on its strategic acquisitions and partnerships supporting each of the three legs of its strategy.

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Strong domestic and international performance by Omnipod is driving the top line for Insulet (PODD).

CVS Health (CVS) Retail Business Grows Despite Cost Pressure

by Zacks Equity Research

CVS Health's (CVS) retail business sees solid rebound in front-store sales with strength across all categories.

SmileDirectClub (SDC) to Boost Europe Presence, Enter France

by Zacks Equity Research

SmileDirectClub (SDC) since its foray into Europe in 2019 has been seeing remarkable market penetration of its oral care products.

Neogen (NEOG) Q1 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Strong segmental performance and contributions from new acquisitions and product launches drove Neogen's (NEOG) revenues in the first quarter of fiscal 2022.

Medtronic (MDT) Starts Pediatric Trial for Scoliosis Treatment

by Zacks Equity Research

Medtronic's (MDT) BRAIVE IDE study will assess the safety and efficacy of growth modulation system in correcting the spine's curve in patients with juvenile or adolescent idiopathic scoliosis.

Boston Scientific (BSX) Strategic Buyouts Aid Amid Cost Woes

by Zacks Equity Research

Boston Scientific (BSX) is optimistic about its recent deal to acquire Israel-based Lumenis that develops and commercializes energy-based medical solutions.

NextGen's (NXGN) New Partnership to Boost Patient Experience

by Zacks Equity Research

NextGen (NXGN) collaborates with Clinect Healthcare to extend patient-provider connection.

Here's Why You Should Invest in Align Technology (ALGN) Now

by Zacks Equity Research

Investors continue to be optimistic about Align Technology (ALGN) on robust second-quarter 2021 performance and raised guidance.

Boston Scientific's (BSX) New Buyout to Aid Clot Management

by Zacks Equity Research

The acquisition of Devoro Medical by Boston Scientific (BSX) is expected to advance the company's core emphasis on clot management.

Abbott's (ABT) Portico With FlexNav System Gets FDA Approval

by Zacks Equity Research

Abbott's (ABT) Portico with FlexNav TAVR system is intended to treat people with symptomatic severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Here's Why You Should Hold on to LHC Group (LHCG) Stock Now

by Zacks Equity Research

LHC Group (LHCG) continues to benefit from strategic deals and broad array of services.

Here's Why You Should Retain Walgreens (WBA) Stock for Now

by Zacks Equity Research

Investors are optimistic about Walgreens (WBA), given the strong performance in the International segment and notable product launches.

NEOGEN (NEOG) to Enter Retail Parasiticide Space With New Buyout

by Zacks Equity Research

NEOGEN's (NEOG) acquisition of CAPInnoVet expands its Animal Safety division and offers a strategic entry into the retail parasiticide market.

Veeva Systems' (VEEV) Cloud Applications Get Adopted by Emmes

by Zacks Equity Research

Veeva Systems' (VEEV) Development Cloud applications to aid in connected drug development.

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

Fresenius Medical's (FMS) Deal to Boost Home Dialysis in Japan

by Zacks Equity Research

Fresenius Medical (FMS) partners with JMS Co. Ltd. to provide innovative home dialysis therapies to the aging population in Japan to improve their wellbeing.

Henry Schein (HSIC) Betters Strategic View With Restructure Plan

by Zacks Equity Research

Henry Schein's (HSIC) new organizational structure will continue to enhance the company's exposure to faster-growing and higher-margin markets.

Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and solid global performance.

Quest Diagnostics' (DGX) COVID-19 Test Demand Up in Q3 Months

by Zacks Equity Research

The "Path Out of the Pandemic" plan of the U.S. Government, while emphasizing more on a magnified access for testing, comes as a major breakthrough for Quest Diagnostics (DGX).

NextGen's (NXGN) New Collaboration to Boost Solutions Portfolio

by Zacks Equity Research

NextGen (NXGN) and Klamath partner to deliver large-scale COVID-19 vaccinations.